5863.50
-0.06%
ICICI Securities Limited
Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).
Number of FII/FPI investors increased from 589 to 613 in Dec 2025 qtr.
More from Alkem Laboratories Ltd.
Recommended